CervoMed Inc. (CRVO)
Automate Your Wheel Strategy on CRVO
With Tiblio's Option Bot, you can configure your own wheel strategy including CRVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRVO
- Rev/Share 0.3779
- Book/Share 3.9797
- PB 1.8946
- Debt/Equity 0.0
- CurrentRatio 20.7339
- ROIC -0.5702
- MktCap 65618509.0
- FreeCF/Share -2.5556
- PFCF -2.9504
- PE -3.5146
- Debt/Assets 0.0
- DivYield 0
- ROE -0.4407
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CRVO | Chardan Capital Markets | Neutral | Buy | -- | $14 | March 13, 2025 |
| Downgrade | CRVO | H.C. Wainwright | Buy | Neutral | -- | -- | Dec. 17, 2024 |
| Downgrade | CRVO | Morgan Stanley | Overweight | Underweight | -- | -- | Dec. 11, 2024 |
| Downgrade | CRVO | Chardan Capital Markets | Buy | Neutral | -- | -- | Dec. 11, 2024 |
| Downgrade | CRVO | D. Boral Capital | Buy | Hold | -- | -- | Dec. 10, 2024 |
| Initiation | CRVO | ROTH MKM | -- | Buy | -- | $45 | Dec. 6, 2024 |
| Initiation | CRVO | H.C. Wainwright | -- | Buy | -- | $42 | Dec. 5, 2024 |
| Initiation | CRVO | Chardan Capital Markets | -- | Buy | -- | $55 | Sept. 18, 2024 |
News
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
CervoMed Inc. (CRVO) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.41 per share a year ago.
Read More
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB)
Read More
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Positive
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.
Read More
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).
Read More
About CervoMed Inc. (CRVO)
- IPO Date 2008-05-23
- Website https://www.cervomed.com
- Industry Biotechnology
- CEO Dr. John J. Alam M.D.
- Employees 15